Peritoneal dialysis: Where is it now and where is it going?

International Journal of Artificial Organs

Volumn 27, Issue 2, 2004, Pages 88-94

  Oreopoulos, Dimitrios G ^a   Lobbedez, T ^a   Gupta, S ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PERITONEAL DIALYSIS;

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; DIALYSIS FLUID;

ATHEROSCLEROSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; EDITORIAL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTERMETHOD COMPARISON; KIDNEY CLEARANCE; MALNUTRITION; MORTALITY; PERITONEAL CATHETER; PERITONITIS; QUALITY OF LIFE; SOLUTE; SURVIVAL RATE; ULTRAFILTRATION; UREMIA; URINE VOLUME;

EID: 1842451611     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880402700203     Document Type: Editorial

References (63)

1. Popovich RP, Moncrief JW, Dechert JF, Bomar JB, Pyle WK. The definition of a novel portable/wearable equilibrium dialysis technique. (Abstract). Trans Am Soc Artif Intern Organs 1976; 5: 64.
2. Oreopoulos DG, Robson M, Izatt S, Clayton S, de Veber GA. A simple and safe technique for CAPD. Trans Am Soc Artif Intern Organs 1978; 24: 484-9.
3. Buoncristiani U, Bianchi P, Cozzari M. A new safe simple connection system for CAPD. Int J Nephrol Androl 1980; 1: 50-3.
4. Gokal R. Taking peritoneal dialysis beyond the year 2000. Perit Dial Int 1999; 19 (suppl 3): S35-42.
5. Gokal R, Mallick NP. Peritoneal dialysis. Lancet 1999; 353: 823-8.
6. Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Moo Y, Copleston P, Jeffery JR, Kjellstrand CM. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. Am J Kidney Dis 1997; 30: 334-42.
7. Gokal R. Peritoneal dialysis in the 21st century: An analysis of current problems and future developments. J Am Soc Nephrol 2002; 13 (suppl 1): S104-16.
8. Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B, Nolph KD, Pollock CA, Prowant B, Farrell PC. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37: 598-604.
9. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-64.
10. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002; 61: 256-65.
11. Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-62.
12. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT; NECOSAD Study Group. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41: 1293-302.
13. Wang AY, Sea MM, Ip R, Law MC, Chow KM, Lui SF, Li PK, Woo J. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001; 12: 2450-7.
14. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16: 2207-13.
15. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238-43.
16. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003 15; 139: 105-12.
17. Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis a cost-utility analysis. Perit Dial Int 2002; 22: 39-47.
18. Goree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995; 18: 455-64.
19. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-8.
20. Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 2002; 13 (suppl 1): S37-40.
21. Apostolou T, Gokal R. Quality of life after peritoneal dialysis. In: Gokal R, Khanna R, Krediet R, Nolph K, eds. Text book of peritoneal dialysis. Klewer Academic Press, 2000; pp 709-735.
22. Julius M, Kneisley JD, Carpentier-Alting P, Hawthorne VM, Wolfe RA, Port FK. A comparison of employment rates of patients treated with continuous ambulatory peritoneal dialysis vs in-center hemodialysis (Michigan End-Stage Renal Disease Study). Arch Intern Med 1989; 149: 839-42.
23. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999; 55: 1553-9.
24. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG, Ma JZ. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34: 1065-74.
25. House AA, Pham B, Page DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant 1998; 13: 1763-9.
26. Selgas R, Martinez-Zapico R, Bajo MA, Romero JR, Munoz J, Rinon C, Miranda B, Miguel JL. Prevalence of hepatitis C antibodies (HCV) in a dialysis population at one center. Perit Dial Int 1992; 12: 28-30.
27. Cendoroglo Neto M, Draibe SA, Silva AE, Ferraz ML, Granato C, Pereira CA, Sesso RC, Gaspar AM, Ajzen H. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: Evidence for environmental transmission. Nephrol Dial Transplant 1995; 10: 240-6.
28. Abbott KC, Agodoa LY. Etiology of bacterial septicemia in chronic dialysis patients in the United States. Clin Nephrol 2001; 56: 124-31.
29. Van Biensen W, Vanholder R, Van Loo A, Van der Vennet M, Lameire N. Peritoneal dialysis favorably influences early graft function after renal transplantation compared to haemodialysis. Transplantation 2000; 69: 508-14.
30. Van Biesen W, Dequidt C, Vijt D, Vanholder R, Lameire N. Analysis of the reasons for transfers between hemodialysis and peritoneal dialysis and their effect on survivals. Adv Perit Dial 1998; 14: 90-4.
31. Maitra S, Burkart J, Fine A, Prichard S, Bernardini J, Jindal KK, Oreopoulos DG. Patients on chronic peritoneal dialysis for ten years or more in North America. Perit Dial Int 2000; 20 (suppl 2): S127-33.
32. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 2000; 11: 116-25.
33. Thodis E, Bhaskaran S, Pasadakis P, Bargman JM, Vas SI, Oreopoulos DG. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18: 261-70.
34. Nakamoto H. Kawaguchi Y. Suzuki H. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial 2002; 18: 119-23.
35. Teehan BP, Scheifler CR, Sigler MH, Gilgore GS. A quantitative approach to the CAPD prescription. Perit Dial Bull 1985; 5: 152-6.
36. Maiorca R, Brunori G, Zubani R, Cancarini GC, Manili L, Camerini C, Movilli E, Pola A, d'Avolio G, Gelatti U. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 1995; 10: 2295-305.
37. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996; 7: 198-207.
38. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S; Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-20.
39. Oreopoulos DG. Beyond Kt/V: Redefining adequacy of dialysis in the 21st century. Int Urol Nephrol 2002; 34:393-403.
40. Liakopoulos V, Krishnan M, Savaj S, Khandelwal M, Ghareeb S, Musso C, Vas S, Bargman JM, Jassal SV, Oreopoulos DG. Improvement of uremic symptoms in stable PD patients after increasing dialysis dose. Present at the 17th World Congress of Nephrology, 8-12 June 2003, Berlin, Germany. Nephrol Dial Transplant 2003; 18 (suppl 4): S476.
41. Konings CJ, Kooman JP, Schonck M, et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002; 22: 477-87.
42. Ates K, Nergizoglu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: 767-76.
43. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W, Divino Filho JC, Vonesh E, van Bree M; EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: The European APD Outcome Study. J Am Soc Nephrol 2003; 14: 2948-57.
44. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495-506.
45. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-9.
46. Numata M, Nakayama M, Nimura S, Kawakami M, Lindholm B, Kawaguchi Y. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23: 116-22.
47. Yamamoto R, Nakayama M, Hasegawa T, et al. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial 2002; 18: 131-4.
48. Di Paolo N, Sacchi G, De Mia M, et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron 1986; 44: 204-11.
49. Kjellstrand P, Martinson E, Wieslander A, et al. Degradation in peritoneal dialysis fluids may be avoided by using low pH and high glucose concentration. Perit Dial Int 2001; 21: 338-44.
50. Rippe B, Simonsen O, Heimburger O, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-57.
51. Skoufos L, Topley N, Cooker L, Dawnay A, Millar DJ, CJ Holmes, D Faict. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate buffered peritoneal dialysis fluid. Kidney Int 2003; 64 (suppl 88): S94-9.
52. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The bicarbonate lactate study group. Perit Dial Int 2000; 20: 516-23.
53. Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival. Perit Dial Int 1997; 17: 84-7.
54. Jones M, Hagen T, Boyle CA, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study. Am J Kidney Dis 1998; 32: 761-9.
55. Le Poole C, Weijmer M, van Ittersum F, ter Wee P, Valentijn R, van Geelen J. Clinical effect of a peritoneal dialysis regimen low in glucose and glucose degradation product compared to a standard peritoneal dialysis regimen in new CAPD patients (Abstract). Perit Dial Int 2003; 23 (suppl 1): S52.
56. Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64:1480-6.
57. Bergstrom J, Lindholm B. Malnutrition, cardiac disease and mortality: Integrated point of view. Am J Kidney Dis 1998; 32: 834-41.
58. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-911.
59. Pecoits-Filho R, Carvalho MJ, Chung SH, Divino-Filho JC et al. interleukin 6 system and peritoneal solute transport rate: A longitudinal study (Abstract). J Am Soc Nephrol 2002; 13: 42.
60. Zeier M, Schwenger V, Deppisch R, et al. Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305.
61. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994: 216-22.
62. Di Paolo N, Petrini G, Garosi G, Buoncristiani U, Brardi S, Monaci G. A new self-locating peritoneal catheter. Perit Dial Int 1996; 16: 623-7.
63. Heimburger O, Holmes C, Mujais S. Introduction: Buffer system and biocompatibility in peritoneal dialysis. Kidney Int 2003; 64 (suppl 88): S1-2.